Daxor Corporation DXR, a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Hartford Hospital of Hartford, Connecticut. This will provide Hartford
Hospital with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume. Blood volume abnormalities are observed in a variety of cardiac conditions and have been associated with poor prognosis.
Hartford Hospital will be participating in a multi-center clinical trial (TEAM-HF) which will test whether incorporation of blood volume assessments into treatment decisions can improve the care and
outcomes of patients with heart failure. Dr. Detlef Wencker, director of the heart failure and transplant center, will serve as the local Principal Investigator, and will be joined by Drs. Joseph Radojevic and Jason A. Gluck to conduct the study at Hartford Hospital. The objective of the interventional TEAM-HF Study is to determine whether
correcting any identified blood volume abnormalities in heart failure patients leads to decreased hospitalization and mortality, and an improvement in exercise capacity and quality of life. This trial will enroll 300 heart failure patients from 11 medical centers.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in